differences, representing interday variability. 22 CGM use in type 1 diabetes is becoming more common; however, very little data on its use in type 2 diabetes have been published.
Diabetes management has evolved from the days of bovine and porcine insulin, with the introduction of rapid-and long-acting analogs of human insulin that provide a better simulation of endogenous insulin levels for diabetic patients using insulin. Patients with type 2 diabetes are now served by an increasing variety of oral antidiabetic agents, with many of the newer agents having the advantage of being glucose-dependent in their mechanism of action, thus reducing the risk for hypoglycemia and, thereby, glycemic variability. Hyperglycemia is established as a risk factor for diabetesrelated complications, 11 and the comprehensive Diabetes Complications and Control Trial (DCCT) 11, 20 and United Kingdom Prospective Diabetes Study (UKPDS) 23 have established the long-term benefits of intensive glycemic control for reducing the risk for microvascular complications. Since glycated hemoglobin (HbA 1c ) is a marker of glycemia, [24] [25] [26] the American Diabetes Association's (ADA's) current recommended treatment target is to achieve a HbA 1c level <7%, 27 with the goal of achieving near-normoglycemia without hypoglycemia. 28 There is mounting evidence that glycemic variability is linked to long-term diabetic complications, 4 which would appear to necessitate a review of current diabetes management regimens. This article examines the latest evidence and also discusses the role of glycemic variability in diabetes management and blood glucose monitoring.
Glycemic Variability-A Risk Factor for Diabetes Complications?
While hyperglycemia is known to be a risk factor for diabetes-related complications, the role of glycemic variability is not fully understood.
In Vitro Evidence
It is well-established that the pathophysiology of diabetic complications involves hyperglycemia-induced oxidative stress and excessive glycation. 2, 20 Oxidative stress results from the overproduction of reactive oxygen radicals (ROS). 4 The effect of glycemic variability on ROS levels has been investigated in cell cultures and in patients with type 2 diabetes. 29, 30 Risso et al. demonstrated that in human umbilical vein endothelial cells (HUVECs) there was a marked increase in cellular apoptosis when they were cultured with an intermittent high-glucose medium than with a constantly high-glucose medium.
high-glucose medium versus constant high-glucose medium on high-glucose-ROS generation in HUVECs. 30 Since ROS cannot be directly measured, 20,31 they used the oxidative products 8-hydroxydeoxyguanosine (8-OHdG) 32, 33 and nitrotyrosine as markers of ROS levels. 34 There was a greater production of both 8-OHdG and nitrotyrosine in cells cultured in the intermittent glucose medium.
These in vitro data show that glycemic variability may have a role in the development of diabetic complications.
NF-κB activation and signal transduction are intrinsic to the development of diabetic complications. 35 Schiekofer et al. investigated the effect of changes in glucose levels on the activation of NF-κB in peripheral blood mononuclear cells of healthy volunteers. 35 They observed an increase in NF-κB activation when glucose was raised from 5 to 10mM, with or without insulin, over two hours.
These data suggest that even acute (short-term) changes in blood glucose may be involved in the development of diabetic complications.
Human Clinical Evidence
The DCCT trial evaluated the effect of intensive treatment on the development published another analysis of the seven-point SMBG profiles obtained every three months from the DCCT subjects and showed that mean blood glucose and glycemic variability independently predicted severe hypoglycemia. 39 In 2008, they published a further study analyzing the effect of long-term glycemic variability of HbA 1c on the risk for developing microvascular complications in the DCCT. 40 They found that HbA 1c variability was greater in the conventionally treated group than in the intensive group (HbA 1c SD 0.86 and 0.59, respectively), and the risk for complications was greater when the effects of mean HbA 1c and HbA 1c variability were combined as opposed to using mean HbA 1c alone. These data suggest that long-term glycemic variability may be an additional risk factor for the development of microvascular complications. 40 Monnier et al. have investigated the effect of sustained chronic hyperglycemia and acute glycemic variability on oxidative stress in patients with type 2 diabetes and poor glycemic control who were not using insulin. 41 MAGE was used as a measure of acute glycemic variability. 41 They showed that free radical production measured by 24-hour urinary excretion of isoprostanes (8- 45 showed no significant reduction in cardiovascular outcomes with intensive glycemic control, while the third trial, ACCORD, 46 terminated its glycemic control study early due to increased mortality in participants randomized to the very intensive glycemic control strategy. However, it is important to mention that the lack of meter glucose download data and glycemic variability data in these major trials makes it difficult to make any assumptions on why the intensive control group in these studies did not show a significant reduction in the combined composite of death, non-fatal myocardial infarction (MI), and stroke in spite of improved glycemic control. Furthermore, it has been suggested that severe hypoglycemia may have played an important role in causing increased mortality in the intensive group of the ACCORD participants as well as in some of the participants in the conventional arm of the VADT. In insulin-requiring patients, insulin analogs may also be used to reduce glycemic variability. Such insulin analogs include the rapid-acting insulins lispro, aspart, and glulisine, which have a more rapid onset, greater peak, and shorter duration of action than regular human insulin. 51 These rapid-acting insulin analogs should be administered within 15 minutes of meal consumption. 52 It has also been shown that these newer insulin analogs reduce the risk for hypoglycemia both during the day and noctunally compared with regular human insulin. 51, 53, 54 These rapid-acting insulin analogs may also be useful in patients experiencing periods of acute hyperglycemia.
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Role of Glycemic Variability in Diabetes Management
To address the basal fluctuations in glycemia during the day, one strategy might include administration of long-acting insulin analogs, such as insulin detemir and insulin glargine. 51 These insulins have prolonged activity, a relatively flat time-action profile, and more consistent absorption. 51 One study investigated the effect of insulin detemir and neutral protamine Hagedorn (NPH) in patients with type 2 diabetes, where insulin was titrated weekly to achieve a target fasting plasma glucose and pre-supper glucose levels ≤108mg/dl. 55 This study showed that less glycemic variability occurred with determir compared with NPH, and this has been confirmed by other studies. [55] [56] [57] [58] Another strategy to minimize glycemic fluctuations (fasting and post-prandial) during the day is the administration of multiple injections of rapid-acting insulin analogs for prandial control along with basal insulin. In conclusion, the new insulin analogs are more physiological and conveniently dosed and reduce the potential for hypoglycemia, so there is now the possibility of achieving better glycemic control and subsequently reducing the risk for long-term complications. 52 Future studies are needed to determine the best pharmacological strategies for minimizing glycemic variability and the increased free radical production it causes.
59
Self-monitoring Blood Glucose in Diabetes Management
Diabetes management requires frequent blood glucose monitoring, 16, 60 which is achieved using blood glucose monitoring devices. 16 SMBG is a cornerstone of diabetes management, particularly in those with type 1 diabetes 10-12 and patients with type 2 diabetes using insulin. [12] [13] [14] [15] [16] It has been suggested that since glycemic variability seems to be a risk factor for diabetic complications, it should be monitored through SMBG or CGM. 20, 59, 61, 62 This would allow modification of the treatment strategy to minimize glycemic variability, thereby lowering the risk for complications. 12 The daily use of SMBG along with the diabetes management software can reveal the immediate effect of patient behavior (such as eating, physical activity, and medication) on glucose levels 19 and allow modification of the treatment strategy to minimize glycemic variability, 20 potentially reducing the risk for complications. 20 In patients with diabetes receiving insulin therapy who have glycemic variability (as determined through SMBG), the glucose fluctuations can be minimized by altering the timing, dosage, or frequency of insulin injections. 12 In treating patients with diabetes, it might be helpful to draw up a written schedule of glycemic goals corresponding to stepwise interventions in insulin dosing and timing of meals that are reviewed and adjusted at regular intervals, allowing modification of treatment strategies to minimize glycemic variability and, thereby, improve diabetes management. 18 The contribution of post-prandial excursions to glycemic variability is evident.
Post-prandial glycemia can be monitored using SMBG or CGM to help achieve a more physiological glycemic profile. 17 It is suggested that patients with diabetes check their glycemia at least four times a day (before meals and at bedtime) with a blood glucose meter, with additional measurements if they experience symptoms of hypo-or hyperglycemia or the HbA 1c is not at goal in spite of acceptable control before meals and at bedtime. 17 The ADA has recommended SMBG three or more times daily for patients with type 1 diabetes, but no specific frequency has been recommended for patients with type 2 diabetes who are not on insulin. 27 A recent meeting of a group of experts suggested that patients with type 2 diabetes should base the frequency of glucose monitoring on the extent of diabetes progression and insulin deficiency and the treatment modalities used. 18 It should be noted that SMBG is associated with a few limitations. Its clinical value in patients who are not treated with insulin needs to be fully evaluated. 21 SMBG has been associated with patient compliance issues, 16, 17 but technological improvements to the blood glucose monitors have decreased the non-compliance. 16 The use of CGM devices in type 1 diabetes has been validated, 63 but its benefit and use in type 2 diabetes management is unknown.
SMBG is still a mainstay in diabetes management as it provides detailed information about the quality of glycemic control and thereby allows better diabetes management.
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Conclusions
Diabetes is characterized by sustained chronic hyperglycemia and glycemic variability. Traditionally, diabetes management has focused on achieving normal plasma glucose levels as chronic hyperglycemia is a risk factor for longterm complications. Recent studies have suggested that glycemic variability may be an additional risk factor for the long-term complications of diabetes.
Thus, new diabetes management strategies should also focus on minimizing glycemic variability. Strategies to minimize glycemic variability may include intensive therapy with multiple insulin injections, the use of rapid-acting insulin analogs to reduce periods of acute hyperglycemia, or the use of long-acting insulin analogs to minimize basal or fasting blood glucose variability. The new insulin analogs may help achieve better glycemic control and further reduce the risk for long-term complications. New oral and subcutaneous antidiabetic agents may be used to reduce glycemic variability in patients with type 2 diabetes not using insulin. A fundamental part of diabetes management is SMBG using blood glucose monitoring devices. Diabetes management software can use the data from SMBG to give a measure of glycemic variability.
The use of SMBG along with this software will allow the patient to monitor glycemic excursions and identify any effect of behavior or treatment schedule on glycemic variability and control. If needed, the patient can then adjust the treatment regimen or behavior to minimize glycemic variability and, potentially, reduce the risk for diabetic complications. Large-scale studies are needed to validate the impact of reducing glycemic variability with these new treatment strategies, and monitoring systems will in fact reduce long-term complications of diabetes. ■
